Preoperative Levels of Matrix Metalloproteinase-7 and-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients
| dc.contributor.author | Gunes, M | |
| dc.contributor.author | Kemik, AS | |
| dc.contributor.author | Pirincci, N | |
| dc.contributor.author | Gecit, I | |
| dc.contributor.author | Taken, K | |
| dc.contributor.author | Yuksel, MB | |
| dc.contributor.author | Kaba, M | |
| dc.contributor.author | Eryilmaz, R | |
| dc.date.accessioned | 2025-04-10T10:36:19Z | |
| dc.date.available | 2025-04-10T10:36:19Z | |
| dc.description.abstract | Our aim was to test the hypothesis that preoperative serum levels of matrix metalloproteinase-7 (MMP-7) and -9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) levels correlate with pathological features. Serum levels of MMP-7, and MMP-9 and TIMP-1 were determined in 90 bladder cancer patients and 40 healthy controls using an enzyme linked immunosorbent assay. Preoperative serum MMP-7 and MMP-9 levels were significantly higher in cancer patients than control groups (p<0.001). In contast, serum TIMP-1 levels were lower (p<0.001). Alteration in MMP-7, and MMP-9, and TIMP-1 production may contribute to tumor angiogenesis and be associated with clinic-pathological features. | |
| dc.identifier.issn | 1513-7368 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/42205 | |
| dc.language.iso | English | |
| dc.title | Preoperative Levels of Matrix Metalloproteinase-7 and-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients | |
| dc.type | Article |